Huw Nash is the chief business officer of Stoke Therapeutics and was previously the founding chief executive officer and chief operating officer. An entrepreneur-in-residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing startup biotechnology companies. Prior to Stoke, Huw was a co-founder and vice president of corporate development for Aileron Therapeutics. He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as vice president of external collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in biochemical sciences from Harvard College and earned his Ph.D. in organic chemistry from Harvard University.